Equetro and Polatuzumab vedotin

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling. MANAGEMENT: Concomitant use of polatuzumab vedotin with potent CYP450 3A4 inducers should be avoided, if possible, due to the potential for reduced efficacy. References "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.

GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 may decrease exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with rifampin, a potent CYP450 3A4 inducer, is predicted to decrease unconjugated MMAE exposure (AUC) by 63% according to the product labeling.

MANAGEMENT: Concomitant use of polatuzumab vedotin with potent CYP450 3A4 inducers should be avoided, if possible, due to the potential for reduced efficacy.

Equetro

Generic Name: carbamazepine

Brand name: Carbatrol, Epitol, Equetro, Tegretol, Tegretol XR, Tegretol, Tegretol XR

Synonyms: n.a.

What is Equetro?

Polatuzumab vedotin

Generic Name: polatuzumab vedotin

Brand name: Polivy

Synonyms: Polatuzumab Vedotin

What is Polatuzumab vedotin?